MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte issues stock options and RSUs as an inducement grant to its new Senior Vice-President, Chief Corporate Development Officer.

Rhea-AI Summary

MaxCyte (MXCT) granted inducement equity awards to Sidharth Kapileshwar in connection with his appointment as Senior Vice-President, Chief Corporate Development Officer, effective August 31, 2026.

The awards comprise stock options to purchase an aggregate of 220,000 shares of common stock and a service-based restricted stock unit award covering 110,000 shares, all issued under the company’s 2026 Inducement Plan in reliance on Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% after one year and the remainder monthly over the following 36 months, have a ten-year term, and carry an exercise price of $1.29, the August 31, 2026 Nasdaq closing price. The RSUs vest over four years, with 25% after one year from August 31, 2026 and the balance in three equal annual installments, in each case subject to continuous service.

Positive

• 330,000 total inducement equity awards help align new officer’s incentives with shareholders
• Four-year vesting schedule for options and RSUs supports management retention and long-term focus

Negative

• Inducement awards for 330,000 shares introduce incremental potential equity dilution for existing shareholders

Key Figures

Stock options: 220,000 shares Restricted stock units: 110,000 shares Exercise price: $1.29 +3 more

Stock options

220,000 shares

Inducement award for new Chief Corporate Development Officer

Restricted stock units

110,000 shares

Service-based inducement award

Exercise price

$1.29

Stock options granted August 31, 2026

Option term

10 years

Term of inducement stock options

Option vesting

4 years

25% after one year; remainder monthly over 36 months

RSU vesting

4 years

25% after one year; remainder in three annual installments

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock unit financial

"a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte’s common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer at MaxCyte. The awards were granted under the MaxCyte, Inc. 2026 Inducement Plan (the “Plan”) with a grant date of August 31, 2026 as an inducement material to entering into employment with MaxCyte, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options are scheduled to vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the 36-month period thereafter, subject to the employee’s continuous service with MaxCyte through the applicable vesting dates. The stock options have a ten-year term and an exercise price of $1.29, the closing price of MaxCyte’s common stock as reported by Nasdaq on August 31, 2026.

The RSUs are scheduled to vest over four years, with 25% vesting on the first anniversary of August 31, 2026 and the remainder vesting in three equal annual installments thereafter, subject to the employee’s continuous service with MaxCyte through the applicable vesting dates.

MaxCyte is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About MaxCyte

At MaxCyte^®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation^® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. 

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
Erik Abdow
ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060